Key points
- SomnoMed reported a 3% increase in revenue for FY26, reaching $114.5 million
- EBITDA increased by 19% to $10.9 million, with margins improving to 9.6%
- The company experienced operational resilience despite second-half headwinds in Europe
- A new oral appliance, Virtus, was introduced to address sleep bruxism in OSA patients
- Leadership transition saw Karen Borg appointed as CEO
Full summary
SomnoMed Ltd has released its 2026 Full Year Report, highlighting a 3% increase in revenue to $114.5 million. The company's EBITDA improved by 19% to $10.9 million, with EBITDA margins rising to 9.6%. Despite facing second-half headwinds in Europe, SomnoMed demonstrated operational resilience. North America contributed significantly to the revenue growth, with a 12% increase in constant currency terms. The company also introduced Virtus, a new oral appliance designed for obstructive sleep apnea (OSA) patients who suffer from sleep bruxism. Leadership changes included Karen Borg taking over as CEO, and Greg Knight being promoted to Chief Operating Officer. The company is targeting high single-digit revenue growth for FY27 while maintaining EBITDA margins consistent with FY26.
Guidance
FY27 expected high single-digit revenue growth, EBITDA margins consistent with FY26
Outlook
SomnoMed is targeting high single-digit revenue growth for FY27 while maintaining EBITDA margins consistent with FY26. The company expects continued growth in North America and stabilization in Europe, with successful global adoption of Virtus in H2 FY27.